PMID- 31061617
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 1319-0164 (Print)
IS  - 2213-7475 (Electronic)
IS  - 1319-0164 (Linking)
VI  - 27
IP  - 4
DP  - 2019 May
TI  - Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic 
      acid co-polymer.
PG  - 491-501
LID - 10.1016/j.jsps.2019.01.012 [doi]
AB  - Baricitinib is a recently approved anti-rheumatic drug having very poor aqueous 
      solubility and hence its performance suffers from low or inconsistent oral 
      bioavailability. The purpose of the study was to develop and evaluate poly 
      lactic-co-glycolic acid (PLGA) nanoparticles of baricitinib in order to enhance 
      in vitro dissolution and performance. Nano-suspension of baricitinib with or 
      without PLGA, a biodegradable, FDA approved semi-synthetic polymer, was developed 
      by nanoprecipitation method. Research methodology employed a quantitative 
      research utilizing experimental design wherein effect of independent variables 
      such as amount of polymer, drug: polymer ratio, types of solvent, and solvent: 
      anti-solvent ratio were evaluated over the size and size distribution of 
      nanoparticles along with entrapment efficiencies. Among the several organic 
      phases evaluated, acetone was found to be suitable solvent for drug and polymer. 
      The aqueous phase (anti-solvent) was deionized water containing 1% w/v pluronic 
      127 as the stabilizer of nanoparticle suspension. The optimized nanoparticles had 
      particle size less than 100 nm (91 nm +/- 6.23) with a very narrow size 
      distribution (0.169 +/- 0.003), high zeta potential (-12.5 mV +/- 5.46) and 
      entrapment efficiency (88.0%). The optimized nanoparticles were characterized by 
      scanning electron microscopy, X-ray diffraction, differential scanning 
      calorimetry, infrared spectroscopy and in vitro dissolution studies. In-vitro 
      dissolution study of PLGA nanoparticles exhibited sustained release with 
      approximately 93% release of baricitinib during 24-h period.
FAU - Ansari, Mohammad Javed
AU  - Ansari MJ
AD  - Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Alkharj, Saudi Arabia.
FAU - Alshahrani, Saad M
AU  - Alshahrani SM
AD  - Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz 
      University, Alkharj, Saudi Arabia.
LA  - eng
PT  - Journal Article
DEP - 20190112
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi 
      Pharmaceutical Society
JID - 9705695
PMC - PMC6488806
OTO - NOTNLM
OT  - Baricitinib
OT  - Dissolution
OT  - Encapsulation
OT  - Nanoparticles
OT  - Nanoprecipitation
OT  - Solubility
EDAT- 2019/05/08 06:00
MHDA- 2019/05/08 06:01
PMCR- 2019/01/12
CRDT- 2019/05/08 06:00
PHST- 2018/11/15 00:00 [received]
PHST- 2019/01/10 00:00 [accepted]
PHST- 2019/05/08 06:00 [entrez]
PHST- 2019/05/08 06:00 [pubmed]
PHST- 2019/05/08 06:01 [medline]
PHST- 2019/01/12 00:00 [pmc-release]
AID - S1319-0164(19)30011-8 [pii]
AID - 10.1016/j.jsps.2019.01.012 [doi]
PST - ppublish
SO  - Saudi Pharm J. 2019 May;27(4):491-501. doi: 10.1016/j.jsps.2019.01.012. Epub 2019 
      Jan 12.